Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)
Phase of Trial: Phase IV
Latest Information Update: 21 May 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms REALME
- 10 Jun 2017 Biomarkers information updated
- 12 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
- 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.